Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | active not recruiting | Phase 2 / Phase 3 | 363 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma(EPCORE™FL-2) | active not recruiting | Phase 3 | 1,095 | GenmabINDUSTRY |
| 32 |
| Aug 4, 2026 |
| clinicaltrials |
| NCT02443077 | Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | active not recruiting | Phase 3 | 94 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT03914625 | A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | active not recruiting | Phase 3 | 6,720 | National Cancer Institute (NCI)NIH | 5 | Jul 30, 2026 | clinicaltrials |
| NCT04939090 | Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | active not recruiting | Phase 3 | 227 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05457556 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | active not recruiting | Phase 3 | 66 | Children's Oncology GroupNETWORK | 3 | Jul 30, 2026 | clinicaltrials |
| NCT02101853 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 669 | National Cancer Institute (NCI)NIH | 5 | Jul 29, 2026 | clinicaltrials |
| NCT02112916 | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | active not recruiting | Phase 3 | 847 | National Cancer Institute (NCI)NIH | 4 | Jul 29, 2026 | clinicaltrials |
| NCT02166463 | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | active not recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 3 | Jul 29, 2026 | clinicaltrials |
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma(iMMagine-3) | active not recruiting | Phase 3 | 452 | Kite, A Gilead CompanyINDUSTRY | 15 | Jul 29, 2026 | clinicaltrials |
| NCT02970318 | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | active not recruiting | Phase 3 | 310 | Acerta Pharma BVINDUSTRY | 25 | Jul 24, 2026 | clinicaltrials |
| NCT04212013 | A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma | active not recruiting | Phase 3 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04285086 | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance(SURPASS ET) | active not recruiting | Phase 3 | 174 | PharmaEssentiaINDUSTRY | 8 | Jul 22, 2026 | clinicaltrials |
| NCT04404283 | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL(ECHELON-3) | active not recruiting | Phase 3 | 239 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 14 | Jul 22, 2026 | clinicaltrials |
| NCT05735834 | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients(RITZ) | active not recruiting | Phase 3 | 122 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 8 | Jul 22, 2026 | clinicaltrials |
| NCT03020030 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | active not recruiting | Phase 3 | 560 | Dana-Farber Cancer InstituteOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT04483739 | Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)(IsKia) | active not recruiting | Phase 3 | 302 | European Myeloma Network B.V.NETWORK | 8 | Jul 16, 2026 | clinicaltrials |
| NCT04717414 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions(INDEPENDENCE) | active not recruiting | Phase 3 | 313 | CelgeneINDUSTRY | 26 | Jul 16, 2026 | clinicaltrials |
| NCT04712097 | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma(Celestimo) | active not recruiting | Phase 3 | 478 | Hoffmann-La RocheINDUSTRY | 15 | Jul 10, 2026 | clinicaltrials |
| NCT04576156 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | active not recruiting | Phase 3 | 327 | Geron CorporationINDUSTRY | 26 | Jul 8, 2026 | clinicaltrials |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | active not recruiting | Phase 2 / Phase 3 | 422 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05409066 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma(EPCORE FL-1) | active not recruiting | Phase 3 | 549 | GenmabINDUSTRY | 30 | Jul 8, 2026 | clinicaltrials |
| NCT04408638 | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 3 | 270 | Hoffmann-La RocheINDUSTRY | 13 | Jul 7, 2026 | clinicaltrials |
| NCT06356129 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma(GOLSEEK-1) | active not recruiting | Phase 3 | 850 | CelgeneINDUSTRY | 38 | Jul 6, 2026 | clinicaltrials |
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | active not recruiting | Phase 3 | 125 | Alexion Pharmaceuticals, Inc.INDUSTRY | 19 | Jul 2, 2026 | clinicaltrials |
| NCT06578247 | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML(QuANTUM-WILD) | active not recruiting | Phase 3 | 700 | Daiichi SankyoINDUSTRY | 28 | Jul 2, 2026 | clinicaltrials |
| NCT04162210 | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM-3) | active not recruiting | Phase 3 | 325 | GlaxoSmithKlineINDUSTRY | 19 | Jul 1, 2026 | clinicaltrials |
| NCT02724163 | International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia(Myechild01) | active not recruiting | Phase 3 | 700 | University of BirminghamOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT03173248 | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation(AGILE) | active not recruiting | Phase 3 | 146 | Institut de Recherches Internationales ServierOTHER | 20 | Jun 29, 2026 | clinicaltrials |
| NCT05058404 | Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma | active not recruiting | Phase 3 | 605 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04090736 | Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy(PEVOLAM) | active not recruiting | Phase 3 | 302 | PETHEMA FoundationOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04529772 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)(ESCALADE) | active not recruiting | Phase 3 | 611 | Acerta Pharma BVINDUSTRY | 23 | Jun 25, 2026 | clinicaltrials |
| NCT03117751 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | active not recruiting | Phase 2 / Phase 3 | 790 | St. Jude Children's Research HospitalOTHER | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | active not recruiting | Phase 3 | 281 | Alexion Pharmaceuticals, Inc.INDUSTRY | 19 | Jun 17, 2026 | clinicaltrials |
| NCT04484623 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma(DREAMM 8) | active not recruiting | Phase 3 | 302 | GlaxoSmithKlineINDUSTRY | 18 | Jun 12, 2026 | clinicaltrials |
| NCT06956170 | All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma(DREAMM 8) | active not recruiting | Phase 3 | 21 | GlaxoSmithKlineINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy(Viale-a) | active not recruiting | Phase 3 | 443 | AbbVieINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT01046825 | Mature B-Cell Lymphoma And Leukemia Study III | active not recruiting | Phase 2 / Phase 3 | 128 | St. Jude Children's Research HospitalOTHER | 3 | Jun 2, 2026 | clinicaltrials |
| NCT02972840 | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | active not recruiting | Phase 3 | 635 | Acerta Pharma BVINDUSTRY | 27 | Jun 1, 2026 | clinicaltrials |
| NCT00734877 | UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma(TT4B) | active not recruiting | Phase 3 | 382 | University of ArkansasOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04628494 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)(EPCORE DLBCL-1) | active not recruiting | Phase 3 | 483 | GenmabINDUSTRY | 24 | May 22, 2026 | clinicaltrials |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | active not recruiting | Phase 3 | 165 | AbbVieINDUSTRY | 23 | May 13, 2026 | clinicaltrials |
| NCT06230224 | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma(OLYMPIA-4) | active not recruiting | Phase 3 | 216 | Regeneron PharmaceuticalsINDUSTRY | 14 | May 11, 2026 | clinicaltrials |
| NCT04217278 | A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT(COSI) | active not recruiting | Phase 2 / Phase 3 | 333 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05429268 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)(firmMIND) | active not recruiting | Phase 3 | 82 | Incyte CorporationINDUSTRY | 14 | May 5, 2026 | clinicaltrials |
| NCT07226752 | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China | active not recruiting | Phase 3 | 72 | GenmabINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT03319667 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant(IMROZ) | active not recruiting | Phase 3 | 475 | SanofiINDUSTRY | 21 | May 4, 2026 | clinicaltrials |
| NCT03206671 | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents(B-NHL 2013) | active not recruiting | Phase 3 | 650 | University Hospital MuensterOTHER | 8 | Apr 30, 2026 | clinicaltrials |
| NCT04384484 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(LOTIS 5) | active not recruiting | Phase 3 | 440 | ADC Therapeutics S.A.INDUSTRY | 21 | Apr 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 4, 2026source: clinicaltrials